Codex DNA, Inc. Announces Departure of Timothy E. Cloutier as Senior Vice President, Effective September 17, 2021
September 16, 2021 at 05:03 pm EDT
Share
Codex DNA, Inc. and Timothy E. Cloutier have entered into an agreement (the Separation Agreement) pursuant to which Mr. Cloutier will depart the Company on September 17, 2021. Under the Separation Agreement, Mr. Cloutier will be entitled to various severance benefits previously approved by the Company’s Board of Directors for employees at the Senior Vice President level in the Company. Mr. Cloutier’s receipt of the Severance Benefits was subject to his execution of the Separation Agreement, which contains, among other provisions, a general release and waiver of claims. Mr. Cloutier’s departure was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
Telesis Bio Inc. is a provider of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) solutions. The Company provides automated multi-omic and synthetic biology solutions focused on providing applications to enable researchers to rapidly and reproducibly build or write high-quality synthetic DNA and messenger Ribonucleic Acid (mRNA) and short oligonucleotides that are ready to use in many downstream synthetic biology enabled markets. Its BioXp system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. Its on-market and its planned solutions include BioXp 3250 system, BioXp 9600 system, BioXp portal, BioXp De Novo kits, BioXp Select kits, BioXp Next Generation Sequencing kits, Benchtop reagents and Custom Gibson Short Oligo Ligation Assembly (SOLA) enzymatic DNA synthesis (EDS) solutions. BioXp Select kits offer customers the ability to use non-Telesis Bio DNA while using the BioXp system to perform synthetic biology workflow applications.